Aurora Daljit Singh 4

Accession 0000950170-25-022320

CIK 0001885522other

View on SEC.gov Company Profile

Filed

Feb 17, 7:00 PM ET

Accepted

Feb 18, 4:30 PM ET

Size

37.9 KB

Accession

0000950170-25-022320

Insider Transaction Report

Form 4

Period: 2025-02-13

Neumora Therapeutics, Inc.NMRA

Aurora Daljit Singh

See Remarks

Transactions

Award
Stock Option (Right to Buy)
2025-02-13+1,000,000→ 1,000,000 total
Exercise: $1.69Exp: 2035-02-13→ Common Stock (1,000,000 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+207,901→ 207,901 total
Exercise: $1.69Exp: 2033-01-19→ Common Stock (207,901 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+136,210→ 136,210 total(indirect: See footnote)
Exercise: $1.69Exp: 2033-01-19→ Common Stock (136,210 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+72,221→ 72,221 total
Exercise: $1.69Exp: 2033-06-23→ Common Stock (72,221 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+29,737→ 29,737 total(indirect: See footnote)
Exercise: $1.69Exp: 2033-06-23→ Common Stock (29,737 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+195,000→ 195,000 total
Exercise: $1.69Exp: 2034-02-14→ Common Stock (195,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−40,890→ 0 total
Exercise: $4.24Exp: 2031-09-20→ Common Stock (40,890 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−137,538→ 0 total(indirect: See footnote)
Exercise: $4.24Exp: 2031-09-20→ Common Stock (137,538 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−207,901→ 0 total
Exercise: $6.51Exp: 2033-01-19→ Common Stock (207,901 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−136,210→ 0 total(indirect: See footnote)
Exercise: $6.51Exp: 2033-01-19→ Common Stock (136,210 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−72,221→ 0 total
Exercise: $6.36Exp: 2033-06-23→ Common Stock (72,221 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−29,737→ 0 total(indirect: See footnote)
Exercise: $6.36Exp: 2033-06-23→ Common Stock (29,737 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−195,000→ 0 total
Exercise: $18.07Exp: 2034-02-14→ Common Stock (195,000 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+40,890→ 40,890 total
Exercise: $1.69Exp: 2031-09-20→ Common Stock (40,890 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+137,538→ 137,538 total(indirect: See footnote)
Exercise: $1.69Exp: 2031-09-20→ Common Stock (137,538 underlying)

Footnotes (9)

[F1]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F2]25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F3]On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged.
[F4]The stock option is fully vested and exercisable.
[F5]Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries.
[F6]25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F7]25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F8]25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F9]Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

→

Entity typeother

Related Parties

filerCIK 0001793971

Filing Metadata

Form type: 4
Filed: Feb 17, 7:00 PM ET
Accepted: Feb 18, 4:30 PM ET
Size: 37.9 KB

View on SEC.gov